Biotech Startups

TenSixty uses machine learning and cell biology expertise to identify novel antibody targets on cancer cells for the development of new cancer therapeutics. The company combines AI with high-throughput technologies to discover improved drug candidates for oncology.

3 investors

Terray is a drug discovery company that combines proprietary hardware, large-scale experimental datasets, and AI through its EMMI platform to design small molecule medicines. It develops therapeutic candidates by integrating high-throughput experimentation with machine learning.

3 investors

Terremoto Biosciences is a clinical-stage biotech developing precision therapies for oncology and genetic diseases using lysine-targeted covalent chemistry. It pursues both best-in-class treatments against known drug targets and first-in-class medicines against previously undruggable targets.

3 investors

Terrestrial is developing the Tacterra microarray patch (MAP) platform, which uses dissolvable tips made from biomaterials to deliver therapies such as GLP-1 through the skin without injections. The platform is designed for patient self-administration at home or while traveling, removing the need for sharps and refrigeration.

3 investors

TeselaGen offers a cloud-based platform for managing the complete design-build-test-learn cycle in biological research and synthetic biology workflows. The platform connects sequence design, laboratory execution, data capture, and machine-learning analysis to eliminate data silos and ensure traceability across experimental processes.

3 investors

TET Medical develops diagnostics, working in collaboration with Cornell University's research and facilities. The company is supported by administrative and operational staff focused on efficiency and compliance.

3 investors

Biotechnology company with proprietary technology for ion channel antigens in antibody discovery programs.

3 investors

Tetsuwan operates a cloud lab and automation platform called ResearchOS that lets researchers configure, simulate, and run biology experiments from their browser without physical lab access. Users describe procedures and variables in natural language or by uploading files, and the system compiles them into executable robotic automation scripts.

3 investors

Tevard Biosciences develops tRNA-based therapies to provide durable cures for rare genetic diseases caused by nonsense mutations, including cardiomyopathy, muscular dystrophy, and epilepsy. The company uses suppressor tRNA technology to restore full-length protein production across affected organs and tissues.

3 investors

The company uses molecular simulation and AI to engineer breakthrough medicines.

3 investors

Theradaptive develops protein engineering technology that modifies recombinant proteins into material-binding variants for targeted therapeutic delivery, aiming to improve efficacy and reduce off-target effects. Its applications span more than a dozen clinical indications including spinal fusion, orthopedics, soft tissue repair, and targeted chemotherapeutics.

3 investors

Theremia develops statistical methods for analyzing clinical trial outcomes, including a Nearest Neighbor Pairing approach to improve Win Ratio estimation of individual causal treatment effects in heterogeneous patient populations. Its work targets precision medicine and drug benefit-risk assessment, with attention to adverse drug reactions and CNS treatments.

3 investors

3 investors

Nexoplex Bio develops immunotherapies designed to target tumors through recognition of HLA-peptide complexes using multi-specific antibodies, aimed at cancers including certain lung, gastric, esophageal, head and neck, and cervical cancers. The company works at the intersection of cancer genomics and immunotherapy.

3 investors

SyntheX develops the ToRFLEx platform, a first-in-class drug discovery technology that enables screening for compounds that modulate protein-protein interactions and targeted protein degradation for previously inaccessible drug targets identified by geneticists. The company builds an internal oncology pipeline and partners with external organizations to expand adoption of its platform.

3 investors

Takeda is a global pharmaceutical company that develops medicines and treatments for patients, focused on advancing science, technology, and partnerships to create new standards of care.

3 investors

TISSIUM develops biomorphic polymer technology, including proprietary polymers, activation technologies, and delivery devices, to reconstruct damaged tissue and restore its function across multiple therapeutic areas. The company operates an integrated innovation, design, manufacturing, and commercialization platform serving its own programs and co-development partnerships in the medtech industry.

3 investors

Topas Therapeutics develops nanoparticle-based therapies to induce immune tolerance for autoimmune and immune-mediated diseases. Its lead candidate, TPM502, targets liver sinusoidal endothelial cells and is being developed for celiac disease, having completed a Phase 2a study.

3 investors

Transcend Therapeutics develops rapid-acting pharmaceutical treatments for neuropsychiatric diseases, including PTSD and depression, targeting patients unresponsive to current psychiatric medications. The company is a clinical-stage biotech firm focused on neuroscience-based drug development.

3 investors

Transition Bio applies methods from physics, chemistry, biology, and machine learning to study protein biophysics—including protein aggregation, self-assembly, and protein-protein interactions—for developing therapeutics targeting health and disease. The company is a platform-based biotherapeutics developer founded on academic research from the University of Cambridge.

3 investors

Treeline develops therapeutics focused on oncology, leveraging insights from clinical practice and laboratory research. The company serves cancer patients through drug discovery and development.

3 investors

Trevi Therapeutics is a clinical-stage biopharmaceutical company developing Haduvio (oral nalbuphine ER), an investigational therapy for chronic cough that targets the central and peripheral cough reflex arc. It is advancing the treatment for patients with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC).

3 investors

Tribune Therapeutics is a preclinical biopharmaceutical company developing medicines that target CCN protein family signaling (such as CCN2/CTGF) to block fibrotic pathways. Its lead candidate, TRX-44, aims to treat fibrotic diseases affecting organs such as the lungs and kidneys regardless of cause.

3 investors

Trinity Guardion makes the Soteria Bed Barrier, an FDA-cleared, launderable and reusable physical barrier that protects hospital beds and mattresses from patient soiling to reduce Healthcare-Acquired Infections. It sells to healthcare facilities for use on beds, warmers, and incubators from major manufacturers, aiming to cut mattress reprocessing time and improve patient safety.

3 investors